Corporate news
FDA approves Grifols Prolastin®-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency
Prolastin®-C Liquid is the first liquid formulation of an alpha-1 antitrypsin deficiency replacement therapy manufactured in the U.S. The new formulation marks an important milestone in Grifols' ongoing R&D efforts
+ info
+ info
Grifols research lines in Alzheimer's move forward with both treatment and prevention
Grifols has been supporting Alzheimer's research since 2004
+ info
+ info
Grifols increases its revenues by 12.3% to EUR 2,192 million driven by growth of its main divisions
First Half of 2017 Results
+ info
+ info
Highlights
Manufacturing
We are a solid company with an international dimension.
Corporate Commitment
We contribute to improving people's health and wellbeing by offering safe, high quality products produced using the latest environmentally friendly technology.
When a Dream Comes True. An Illustrated History of 75 Years of Grifols
Read When a Dream Comes True: An illustrated history of 75 years of Grifols to discover the company's roots, and learn more about our history and the development of the company. + info